Development of Live and Recombinant Vaccine Against Poultry Enteric Diseases
Animal Biosciences and Biotechnology Laboratory
2011 Annual Report
1a.Objectives (from AD-416)
This Trust Fund Cooperative Agreement is to develop new strategies to induce cross protective immunity to avian coccidiosis using multivalent recombinant coccidiosis vaccine and to investigate immune markers associated with protective immunity.
1b.Approach (from AD-416)
ARS identified several potential vaccine antigens of Eimeria that will be used in vaccination trials at ARS. Two recombinant antigens will be mixed in adjuvants which will be provided by the CAVAC and will be used to immunize broiler chickens at ARS. Challenge will be carried out using E. tenella, E. acervulina, and E. Maxima species and clinical parameters (oocysts, body weight, gut lesions) and various host immune responses (antibody response, T-cell proliferation response, cytokines) will be evaluated.
This agreement is to explore the possibility of initial stage of characterizing host-pathogen interaction in necrotic enteritis and to identify pathogen-associated immunogenic antigens which are involved in protective immune response. Our first experiment to evaluate host-pathogen interaction was carried out and its results are being analyzed.
Progress is monitored by written progress reports, regular teleconferences and meetings.